Home > News > Mirus Bio Corporation Enters Into Agreement With Pfizer Inc.
January 9th, 2007
Mirus Bio Corporation Enters Into Agreement With Pfizer Inc.
Mirus Bio Corporation announced today it has entered into a two year, multimillion dollar agreement with Pfizer Inc. to investigate and optimize gene silencing methods in animal models. The studies will utilize Mirus Bio's nucleic acid delivery platforms to target and suppress the expression of genes of interest to Pfizer.
Nanometrics Announces Upcoming Investor Events July 20th, 2016
Keystone Nano selected as a top scoring company by NCI investor review panel July 19th, 2016
Arrowhead Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference July 6th, 2016
Nanometrics to Participate in the 8th Annual CEO Investor Summit: Investor Event Held Concurrently with SEMICON West 2016 in San Francisco June 22nd, 2016
An accelerated pipeline to open materials research: ORNL workflow system unites imaging, algorithms, and HPC to advance materials discovery and design July 24th, 2016
Russian physicists discover a new approach for building quantum computers: Physicists find a way of 'bundling together' multiple elements of a quantum computer July 24th, 2016
A 'smart dress' for oil-degrading bacteria July 24th, 2016
New superconducting coil improves MRI performance: UH-led research offers higher resolution, shorter scan time July 23rd, 2016